Skip to main content
. 2016 Feb 21;7(13):16146–16157. doi: 10.18632/oncotarget.7550

Figure 3. DC101 treatment increased Ang2 levels, TEM recruitment, and invasive glioma outgrowth.

Figure 3

(A) DC101 treatment induced invasive tumor outgrowth in the GL261 syngeneic model. Tumor sections from mice treated with DC101 or vehicle were stained with hematoxylin and eosin. Scale bars = 200 μm (top) and 50 μm (bottom). (B) Representative images of Iba1 immunostaining of brain sections of GL261-bearing mice treated with DC101 or vehicle. DAPI was used for nuclear staining (blue). Scale bars = 50 μm. (C) Quantification of Iba1+ cells present in a high-power field (HPF) in brain tumors after DC101 treatment. Data are presented as mean ± SD. ***P < 0.001. (D) Representative images of Tie2 (red) and Iba1 (green) double immunofluorescence in sections from GL261 syngeneic tumors treated with DC101 or vehicle. DAPI was used for nuclear staining (blue). Scale bars = 50 μm. (E) Quantification of TEMs (Tie2+Iba1+ cells) present in a HPF after DC101 treatment. Data are presented as mean ± SD. (F) Representative images of Ang2 immunofluorescence in sections from orthotopic GL261-derived gliomas after DC101 treatment. Scale bars = 50 μm. ***P < 0.001.